Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel plus AZD5363 versus paclitaxel plus placebo in triple-negative advanced or metastatic breast cancer
ISRCTN64193273Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial in triple-negative breast cancer (TNBC) comparing AZD5363 + paclitaxel with Placebo + paclitaxel (2 arms). Started May 2014; status: completed.
02
Drugs
capivasertibpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ISRCTN64193273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN64193273.